List of Sancuso drug patents
Sancuso is owned by Kyowa Kirin.
Sancuso contains Granisetron.
Sancuso has a total of 1 drug patent out of which 0 drug patents have expired.
Sancuso was authorised for market use on 12 September, 2008.
Sancuso is available in film, extended release;transdermal dosage forms.
Sancuso can be used as use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting.
The generics of Sancuso are possible to be released after 22 January, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7608282 | KYOWA KIRIN | Transdermal granisetron |
Jan, 2025
(1 year, 7 months from now) | |
Drugs and Companies using GRANISETRON ingredient
Market Authorisation Date: 12 September, 2008
Treatment: Use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
SANCUSO family patents
3
China
3
United States
2
United Kingdom
2
Japan
1
Yugoslavia
1
Georgia
1
Poland
1
Canada
1
Slovenia
1
Korea, Republic of
1
Ukraine
1
Brazil
1
Hong Kong
1
Costa Rica
1
Iceland
1
Germany
1
Morocco
1
Denmark
1
Croatia
1
Spain
1
Mexico
1
New Zealand
1
Australia
1
Norway
1
South Africa
1
Austria
1
Ecuador
1
Portugal
1
Russia
1
Israel
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic